Hanna RM, Barsoum M, Arman F. Nephrotoxicity induced by intravitreal vascular endothelial growth factor inhibitors: emerging evidence. Kidney Int. 2019;96(3):572–80. https://doi.org/10.1016/j.kint.2019.02.042.
Article
CAS
Google Scholar
Hanna RM, Ahdoot RS, Kim MS, Jhaveri KD, Kalantar-Zadeh K, Kurtz IB. Intravitreal vascular endothelial growth factors hypertension, proteinuria, and renal injury: a concise review. Curr Opin Nephrol Hypertens. 2022;31(1):47–56. https://doi.org/10.1097/MNH.0000000000000760.
Article
CAS
Google Scholar
Estrada CC, Maldonado A, Mallipattu SK. Therapeutic inhibition of VEGF signaling and associated nephrotoxicities. J Am Soc Nephrol. 2019;30(2):187–200. https://doi.org/10.1681/ASN.2018080853.
Article
CAS
Google Scholar
Amoaku WM, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L, et al. Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020;34(Suppl 1):1–51. https://doi.org/10.1038/s41433-020-0961-6.
Article
Google Scholar
Tschulakow A, Christner S, Julien S, Ludinsky M, Giet M, Schraermeyer U. Effects of a single intravitreal injection of aflibercept and ranibizumab on glomeruli of monkeys. PLoS ONE. 2014;9(11): e113701. https://doi.org/10.1371/journal.pone.0113701.
Article
CAS
Google Scholar
Glassman AR, Liu D, Jampol LM, Sun JK. Diabetic Retinopathy Clinical Research Network. Changes in blood pressure and urine albumin-creatinine ratio in a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59(3):1199–205. https://doi.org/10.1167/iovs.17-22853.
Article
CAS
Google Scholar
Bagheri SD, Afarid M, Sagheb MM. Proteinuria and renal dysfunction after intravitreal injection of bevacizumab in patients with diabetic nephropathy: a prospective observational study. Galen Med J. 2018;7:e1299. https://doi.org/10.22086/gmj.v0i0.1299.
Article
Google Scholar
Kameda Y, Babazono T, Uchigata Y, Kitano S. Renal function after intravitreal administration of vascular endothelial growth factor inhibitors in patients with diabetes and chronic kidney disease. J Diabetes Investig. 2018;9(4):937–9. https://doi.org/10.1111/jdi.12771.
Article
CAS
Google Scholar
O’Neill RA, Gallagher P, Douglas T, Little JA, Maxwell AP, Silvestri G, et al. Evaluation of longterm intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease. BMC Nephrol. 2019;20(1):478. https://doi.org/10.1186/s12882-019-1650-1.
Article
CAS
Google Scholar
Jalalonmuhali M, Kamalden TAFT, Ismail NS, Yong SY, Teo WT, Lim SK. Adverse renal outcome following administration of intravitreal anti-vascular endothelial growth factor inhibitors in a single tertiary centre in Malaysia. Nephrol Dial Transplant. 2020;142:590. https://doi.org/10.1093/ndt/gfaa142.P0590.
Article
Google Scholar
Chung YR, Kim YH, Byeon HE, Jo DH, Kim JH, Lee K. Effect of a single intravitreal injection of bevacizumab on proteinuria in patients with diabetes. Transl Vis Sci Technol. 2020;9(4):4. https://doi.org/10.1167/tvst.9.4.4.
Article
Google Scholar
Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H. The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye (Lond). 2009;23(8):1714–8. https://doi.org/10.1038/eye.2008.360.
Article
CAS
Google Scholar
Lee K, Yang H, Lim H, Lew HM. A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina. 2009;29(10):1409–17. https://doi.org/10.1097/IAE.0b013e3181b21056.
Article
Google Scholar
Risimic D, Milenkovic S, Nikolic D, Simeunovic D, Jaksic V, Stojkovic M, et al. Influence of intravitreal injection of bevacizumab on systemic blood pressure changes in patients with exudative form of age-related macular degeneration. Hellenic J Cardiol. 2013;54(6):435–40.
Google Scholar
Shah AR, Van Horn AN, Verchinina L, Wichorek M, Su L, Markel D, et al. Blood pressure is associated with receiving intravitreal anti-vascular endothelial growth factor treatment in patients with diabetes. Opththalmol Retina. 2019;3(5):410–6. https://doi.org/10.1016/j.oret.2019.01.019.
Article
Google Scholar
Avery RL, Gordon GM. Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and metaanalysis. JAMA Ophthalmol. 2016;134(1):21–9. https://doi.org/10.1001/jamaophthalmol.2015.4070.
Article
Google Scholar
Hanhart J, Comaneshter DS, Freier Dror Y, Vinker S. Mortality in patients treated with intravitreal bevacizumab for age-related macular degeneration. BMC Ophthalmol. 2017;17(1):189. https://doi.org/10.1186/s12886-017-0586-0.
Article
CAS
Google Scholar
Hanhart J, Comaneshter DS, Freier-Dror Y, Vinker S. Mortality associated with bevacizumab intravitreal injections in age-related macular degeneration patients after acute myocardial infarct: a retrospective population-based survival analysis. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):651–63. https://doi.org/10.1007/s00417-018-3917-9.
Article
CAS
Google Scholar
Hanhart J, Comaneshter DS, Vinker S. Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections. Acta Ophthalmol. 2018;96(6):e732–9. https://doi.org/10.1111/aos.13731.
Article
CAS
Google Scholar
Dalvin LA, Starr MR, AbouChehade JE, Damento GM, Garcia M, Shah SM, et al. Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol. 2019;137(5):483–90. https://doi.org/10.1001/jamaophthalmol.2018.6891.
Article
Google Scholar
Pellé G, Shweke N, Van Huyen J-PD, Tricot L, Hessaïne S, Frémeaux-Bacchi V, et al. Systemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors. Am J Kidney Dis. 2011;57(5):756–9. https://doi.org/10.1053/j.ajkd.2010.11.030.
Article
CAS
Google Scholar
Anto HR, Hyman GF, Li JP, Spitalewitz S, Thomas D. Membranous nephropathy following intravitreal injection of bevacizumab. Can J Ophthalmol. 2012;47(1):84–6. https://doi.org/10.1016/j.jcjo.2011.12.024.
Article
Google Scholar
Cheungpasitporn W, Chebib FT, Cornell LD, Brodin ML, Nasr SH, Schinstock CA, et al. Intravitreal anti-vascular endothelial growth factor therapy may induce proteinuria and antibody mediated injury in renal allografts. Transplant. 2015;99(11):2382–6. https://doi.org/10.1097/TP.0000000000000750.
Article
CAS
Google Scholar
Khneizer G, Al-Taee A, Bastani B. Self-limited membranous nephropathy after Intravitreal nephropathy after intravitreal bevacizumab therapy for age related macular degeneration. J Nephropathol. 2017;6(3):134–7. https://doi.org/10.15171/jnp.2017.23.
Article
Google Scholar
Valsan D, Kazi S. Intravitreal VEGF inhibitor causing allergic interstitial nephritis. Am J Kidney Dis. 2017;69(4):A99. https://doi.org/10.1053/j.ajkd.2017.02.339.
Article
Google Scholar
Hanna RM, Lopez E, Hasnain H, Selamet U, Wilson J, Youssef PN, et al. Three patients with injection of intravitreal vascular endothelial growth facto inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clin Kidney J. 2019;12(1):92–100. https://doi.org/10.1093/ckj/sfy060.
Article
CAS
Google Scholar
Nobakht NN, Nguyen HA, Kamgar MK, Abdelnour L, Rastogi A, Hanna RM. Development of collapsing focal and segmental glomerulosclerosis in a patient receiving intravitreal vascular endothelial growth factor blockade. Kidney Int Rep. 2019;4(10):1508–12. https://doi.org/10.1016/j.ekir.2019.07.019.
Article
Google Scholar
Touzani F, Geers C, Pozdzik A. Intravitreal injection of antiVEGF antibody induces glomerular endothelial cells injury. Case Rep Nephrol. 2019;2019:2919080. https://doi.org/10.1155/2019/2919080.
Article
CAS
Google Scholar
Yin W, Zhang PL. Intravitreal injection of avastin (IIA) over time can be associated with thromobtic microangiopathy (TMA) in the native kidney. J Am Soc Nephrol. 2019;30:153-4.
Shye M, Hanna RM, Patel SS, Tram-Tran N, Hou J, Mccannel C, et al. Worsening proteinuria and renal function after intravitreal vascular endothelial growth factor blockade for diabetic proliferative retinopathy. Clin Kidney J. 2020;13(6):969–80. https://doi.org/10.1093/ckj/sfaa049.
Article
CAS
Google Scholar
Kakeshita K, Koike T, Imamura T, Murai S, Fujioka H, Yamazaki H, et al. Nephrotic syndrome with focal segmental glomerulosclerosis induced by intravitreal injections of vascular endothelial growth factor inhibitor. Intern Med. 2020;59(23):5410–20. https://doi.org/10.2169/internalmedicine.5410-20.
Article
Google Scholar
Hanna RM, Tran NT, Patel SS, Hou J, Jhaveri KD, Parikh R, et al. Thrombotic microangiopathy and acute kidney injury induced after intravitreal injection of vascular endothelial growth factor inhibitors VEGF blockade-related TMA after intravitreal use. Front Med (Lausanne). 2020;7:579603. https://doi.org/10.3389/fmed.2020.579603.
Article
Google Scholar
Hanna RM, Abdelnour L, Zuckerman JE, Ferrey AJ, Pai A, Vahabzadeh K, et al. Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab. SAGE Open Med Case Rep. 2020;8:2050313X20952650. https://doi.org/10.1177/2050313X20952650.
Article
Google Scholar
Phadke G, Hanna RM, Ferrey AJ, Torres EA, Singla A, Kaushal A, et al. Review of intravitreal vascular endothelial growth factor inhibitor toxcitiy, and report of collpasing focal and segmental sclerosis with thrombotic microangiopathy in a patient with age-related macular degeneration. Clin Kidney J. 2021;14(10):2158–65. https://doi.org/10.1093/ckj/sfab066.
Article
Google Scholar
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636–41. https://doi.org/10.1136/bjophthalmol-2014-305252.
Article
Google Scholar
Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, et al. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017;37(10):1847–58. https://doi.org/10.1097/IAE.0000000000001493.
Article
CAS
Google Scholar
Sadiq MA, Halim MS, Hassan M, Onghanseng N, Karaca I, Agarwal A, et al. Pharmacological agents in development for diabetic macular edema. Int J Retina Vitreous. 2020;6:29. https://doi.org/10.1186/s40942-020-00234-z.
Article
Google Scholar
Laszik ZG, Kambham N, Silva FG. Thrombotic Microangiopathies. In: Jannette JC, Olson JL, Silva FG, D’Agati VD, editors. Heptinstall’s Pathology of the Kidney, vol. II. 7th ed. Philadelphia, PA, USA: Wolters Kluwer; 2015. p. 739–814.
Google Scholar
Vincenzo AD, Battini S, Russo L, Mazzocut S, Mauer M, Fioretto P. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020;33(5):901–7. https://doi.org/10.1007/s40620-020-00797-y.
Article
Google Scholar
Person F, Rinschen MM, Brix SR, Wulf S, Noriega MM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019;32(5):684–700. https://doi.org/10.1038/s41379-018-0186-4.
Article
CAS
Google Scholar